Stanford University
Showing 461-480 of 651 Results
-
Laura Graham
Casual - Non-Exempt, Surgery
BioDr. Graham is a health services researcher with extensive experience in data management and analysis, particularly focusing on surgical outcomes research using large administrative datasets from the Veterans Health Administration (VA) and other single site healthcare systems. Her research interests include improving the processes of clinical care using causal inference methodologies and implementation science to translate evidence into practice. Her research has significantly contributed to understanding and improving surgical outcomes, particularly within the VA healthcare system, through rigorous epidemiological and health services research methods.
During her tenure with the Veterans Health Administration and Stanford Medical Center, Dr. Graham's research has focused on using large administrative datasets to improve surgical outcomes, enhance surgical training, and optimize healthcare delivery for veterans undergoing surgical procedures. She has expertise in novel analytic approaches, including causal inference methodologies, and has presented on examining complex relationships and reporting nonlinear trends in surgical outcomes research.
Recently, she led a study mapping the discharge process for surgical patients to identify key components and challenges specific to post-surgical discharge. This work aims to improve care transitions and reduce fragmentation of care for surgical patients. She is currently working on a quasi-experimental study exploring ideal medication combinations for multimodal analgesia. In addition to outcomes research, she has worked on translating evidence into practice through qualitative research methods and implementation science approaches.
Dr. Graham has a substantial publication record, with over 4,600 citations and an h-index of 32 (as of June 2024). Her work has been published in a number of reputable high-impact journals, including JAMA Surgery, Annals of Surgery, and Health Affairs. These experiences have equipped her with a robust understanding of health data and novel data science methodologies, as well as the ability to design and execute complex experiments, analyze data, and communicate results effectively.
In addition to her technical skills, she is a strong collaborator and communicator. She frequently collaborates with clinician-scientists to produce valid and impactful surgical outcomes research. She has successfully led multidisciplinary teams, mentored junior researchers, and fostered productive partnerships with industry and academic collaborators. She is adept at managing multiple projects simultaneously and thrives in dynamic, fast-paced environments. -
Philip Grant
Clinical Associate Professor, Medicine - Infectious Diseases
BioMy research focuses on antiretroviral therapy and complications of HIV including immune reconstitution inflammatory disease, osteoporosis, and cardiovascular disease.
-
Teodor Grantcharov
Professor of Surgery (General Surgery)
BioDr. Teodor Grantcharov completed his surgical training at the University of Copenhagen, and a doctoral degree in Medical Sciences at the University of Aarhus in Denmark.
Dr. Grantcharov is a Professor of Surgery at Stanford University and Associate Chief Quality Officer for Innovation and Safety at Stanford Healthcare.
Prior to joining Stanford, Dr. Grantcharov was a Professor of Surgery at the University of Toronto and Keenan Chair in Surgery at St. Michael’s Hospital in Toronto. He was the Founder of the International Centre for Surgical Safety – a multidisciplinary group of visionary scientists with expertise in design, human factors, computer- and data science, and healthcare research. He previously held Canada Research Chair in Simulation and Surgical Safety and was awarded the Queen Elizabeth II diamond jubilee medal for his contributions to clinical research and patient safety in Canada. Dr. Grantcharov was awarded the honorary fellowship of the Imperial College in London, the honorary fellowships of the Bulgarian, Danish and Brazilian surgical societies, the Spinoza Chair in Surgery from the University of Amsterdam and multiple national and international awards for his contributions to surgical education and surgical safety.
Dr. Grantcharov’s clinical interest is the area of minimally invasive surgery, while his academic focus is in the field of surgical innovation and patient safety. He has become internationally recognized as a leader in this area with his work on curriculum design, assessment of competence and impact of surgical performance on clinical outcomes. Dr. Grantcharov developed the surgical Black Box concept, which aims to transform the safety culture in medicine and introduce modern safety management systems in the high-risk operating room environment.
Dr. Grantcharov has more than 220 peer-reviewed publications and more than 200 invited presentations in Europe, South- and North America. He holds several patents and is the Founder of Surgical Safety Technologies Inc – an academic startup that commercializes the OR Black Box platform. He sits on numerous committees with Surgical Professional Societies in North America and Europe. -
Dita Gratzinger
Professor of Pathology
Current Research and Scholarly InterestsI have research interests in the interaction of hematolymphoid neoplasia with the microenvironment. For example, I use a combination of immunohistochemistry, immunofluorescence and image analysis techniques to evaluate the mesenchymal stromal cell compartment in myelodysplastic syndrome (pre-leukemic bone marrow failure disorder). I also have interests in lymphoma vasculature and the tropism of lymphoma for specific types of vasculature.
-
Edward Graves
Associate Professor of Radiation Oncology (Radiation Physics) and, by courtesy, of Radiology (Molecular Imaging Program at Stanford)
Current Research and Scholarly InterestsApplications of molecular imaging in radiation therapy, development of hypoxia and radiosensitivity imaging techniques, small animal image-guided conformal radiotherapy, image processing and analysis.
-
Nathanael S. Gray
Krishnan-Shah Family Professor
BioNathanael Gray is the Krishnan-Shah Family Professor of Chemical and Systems Biology at Stanford, Co-Director of Cancer Drug Discovery Co-Leader of the Cancer Therapeutics Research Program, Member of Chem-H, and Program Leader for Small Molecule Drug Discovery for the Innovative Medicines Accelerator (IMA). His research utilizes the tools of synthetic chemistry, protein biochemistry, and cancer biology to discover and validate new strategies for the inhibition of anti-cancer targets. Dr. Gray’s research has had broad impact in the areas of kinase inhibitor design and in circumventing drug resistance.
Dr. Gray received his PhD in organic chemistry from the University of California at Berkeley in 1999 after receiving his BS degree with the highest honor award from the same institution in 1995. After completing his PhD, Dr. Gray was recruited to the newly established Genomics Institute of the Novartis Research Foundation (GNF) in San Diego, California. During his six year stay at GNF, Dr. Gray became the director of biological chemistry where he supervised a group of over fifty researchers integrating chemical, biological and pharmacological approaches towards the development of new experimental drugs. Some of the notable accomplishments of Dr. Gray’s team at GNF include: discovery of the first allosteric inhibitors of wild-type and mutant forms of BCR-ABL which resulted in clinical development of ABL001; discovery of the first selective inhibitors of the Anaplastic Lymphoma Kinase (ALK), an achievement that led to the development of now FDA-approved drugs such as ceritinib (LDK378) for the treatment of EML4-ALK expressing non-small cell lung cancer (NSCLC); and discovery that sphingosine-1-phosphate receptor-1 (S1P1) is the pharmacologically relevant target of the immunosuppressant drug Fingomilod (FTY720) followed by the development of Siponimod (BAF312), which is currently used for the treatment of multiple sclerosis.
In 2006, Dr. Gray returned to academia as a faculty member at the Dana Farber Cancer Institute and Harvard Medical School in Boston. There, he has established a discovery chemistry group that focuses on developing first-in-class inhibitors for newly emerging biological targets, including resistant alleles of existing targets, as well as inhibitors of well-validated targets, such as Her3 and RAS, that have previously been considered recalcitrant to small molecule drug development. Dr. Gray’s team developed covalent inhibitors of the T790M mutant of EGFR inspired the development of Osimertinib (AZD9291), now FDA approved for treatment of patients with relapsed lung cancer due to resistance to first generation EGFR inhibitors. Dr. Gray has also developed structure-based, generalized approaches for designing drugs to overcome one of the most common mechanisms of resistance observed against most kinase inhibitor drugs, mutation of the so-called "gatekeeper" residue, which has been observed in resistance to drugs targeting BCR-ABL, c-KIT and PDGFR.
In 2021, Dr. Gray joined Stanford University where he has joined the Stanford Cancer Institute, Chem-H and the Innovative Medicines Accelerator (IMA) to spur the development of prototype drugs.
These contributions have been recognized through numerous awards including the National Science Foundation’s Career award in 2007, the Damon Runyon Foundation Innovator award in 2008, the American Association for Cancer Research for Team Science in 2010 and for Outstanding Achievement in 2011 and the American Chemical Society award for Biological Chemistry in 2011, and the Nancy Lurie Marks endowed professorship in 2015 and the Paul Marks Prize in 2019, and the Hope Funds for Cancer Research in 2023.
